GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Days Sales Outstanding

Kyorin Pharmaceutical Co (TSE:4569) Days Sales Outstanding : 116.25 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Days Sales Outstanding?

Kyorin Pharmaceutical Co's average Accounts Receivable for the three months ended in Dec. 2023 was 円41,186 Mil. Kyorin Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was 円32,330 Mil. Hence, Kyorin Pharmaceutical Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 116.25.

The historical rank and industry rank for Kyorin Pharmaceutical Co's Days Sales Outstanding or its related term are showing as below:

TSE:4569' s Days Sales Outstanding Range Over the Past 10 Years
Min: 131.76   Med: 149.01   Max: 166.07
Current: 131.76

During the past 13 years, Kyorin Pharmaceutical Co's highest Days Sales Outstanding was 166.07. The lowest was 131.76. And the median was 149.01.

TSE:4569's Days Sales Outstanding is ranked worse than
86.17% of 998 companies
in the Drug Manufacturers industry
Industry Median: 71.69 vs TSE:4569: 131.76

Kyorin Pharmaceutical Co's Days Sales Outstanding increased from Dec. 2022 (113.38) to Dec. 2023 (116.25).


Kyorin Pharmaceutical Co Days Sales Outstanding Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Days Sales Outstanding Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.42 166.07 155.88 142.01 143.34

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.38 127.56 147.67 136.83 116.25

Competitive Comparison of Kyorin Pharmaceutical Co's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Days Sales Outstanding falls into.



Kyorin Pharmaceutical Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Kyorin Pharmaceutical Co's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

Days Sales Outstanding (A: Mar. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )*Days in Period
=( (41675 + 47291) / 2 ) / 113270*365
=44483 / 113270*365
=143.34

Kyorin Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (38356 + 44016) / 2 ) / 32330*365 / 4
=41186 / 32330*365 / 4
=116.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Kyorin Pharmaceutical Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines